Aelis Farma SA
Aelis Farma SA, a clinical-stage biopharmaceutical company, focuses on discovering and developing drug candidates for the treatment of central nervous system disorders in France. The company is developing signaling-specific inhibitors of the CB1 receptors, such as AEF0117, a drug candidate, which is in Phase 2b clinical trials for the treatment of the harmful effects of excessive cannabis use; an… Read more
Aelis Farma SA (AELIS) - Total Liabilities
Latest total liabilities as of June 2025: €9.46 Million EUR
Based on the latest financial reports, Aelis Farma SA (AELIS) has total liabilities worth €9.46 Million EUR as of June 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Aelis Farma SA - Total Liabilities Trend (2017–2024)
This chart illustrates how Aelis Farma SA's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Aelis Farma SA Competitors by Total Liabilities
The table below lists competitors of Aelis Farma SA ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
UDAYSHIVAKUMAR INFRA ORD (BSE)
NSE:USK
|
India | ₹1.64 Billion |
|
Starteck Finance Limited
NSE:STARTECK
|
India | ₹3.22 Billion |
|
Wolfden Resources Corporation
PINK:WLFFF
|
USA | $827.13K |
|
VVC Exploration Corporation
OTCQB:VVCVF
|
USA | $12.46 Million |
|
Precio Fishbone AB (publ)
ST:PRCO-B
|
Sweden | Skr55.57 Million |
|
Turnstone Biologics Corp. Common Stock
NASDAQ:TSBX
|
USA | $6.34 Million |
|
Sports Entertainment Group Ltd
AU:SEG
|
Australia | AU$73.86 Million |
|
Jaycorp Bhd
KLSE:7152
|
Malaysia | RM59.79 Million |
Liability Composition Analysis (2017–2024)
This chart breaks down Aelis Farma SA's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 3.18 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | 2.43 | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.55 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.61 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Aelis Farma SA's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Aelis Farma SA (2017–2024)
The table below shows the annual total liabilities of Aelis Farma SA from 2017 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | €9.59 Million | -26.68% |
| 2023-12-31 | €13.08 Million | -32.67% |
| 2022-12-31 | €19.43 Million | -29.13% |
| 2021-12-31 | €27.41 Million | +255.62% |
| 2020-12-31 | €7.71 Million | +28.14% |
| 2019-12-31 | €6.02 Million | +53.59% |
| 2018-12-31 | €3.92 Million | -14.90% |
| 2017-12-31 | €4.60 Million | -- |